How minocycline affects blood pressure in resistant hypertension
Official title: Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the gut microbiota-brain-immune axis
Funded at University of Florida · NIH-11040333 · Data updated 2026-11-12
This study is looking at how the antibiotic minocycline might help people with stubborn high blood pressure by exploring how our gut bacteria, brain, and immune system work together, and it aims to find better ways to manage this condition, especially for those who don't respond well to usual treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | December 15, 2023 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $585,021 |
| NIH project number | 5R01HL132448-06 |
| Project ID | NIH-11040333 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with resistant hypertension who require multiple antihypertensive medications to manage their condition.
✕Less likely to help
Patients with well-controlled hypertension or those who do not meet the criteria for resistant hypertension may not benefit from this research.
What this research studies
This research investigates the effects of minocycline, an antibiotic with anti-inflammatory properties, on patients with resistant hypertension, a condition where blood pressure remains high despite treatment. The study focuses on understanding the role of the gut microbiota and its connection to the brain and immune system in influencing blood pressure. By exploring these mechanisms, the research aims to identify new strategies for managing hypertension, particularly in populations that experience disparities in treatment outcomes. Patients will be monitored for changes in blood pressure and related health markers throughout the study.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with resistant hypertension, improving their blood pressure control and overall cardiovascular health.
How similar studies have gone: Previous research has shown promising results with minocycline in animal models and some human studies, suggesting that this approach may be effective, although it is still being explored in the context of resistant hypertension.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Smith, Steven Michael — University of Florida
- Study coordinator: Smith, Steven Michael
Related research
Other NIH-funded projects on the same topics.
-
Minocycline to lower hard-to-control high blood pressure by targeting the gut–brain–immune link
Looks at whether the antibiotic minocycline can help people with resistant high blood pressure by changing gut bacteria and calming inflammation that affects the brain and immune system.
-
Gut microbiome and Parkinson's disease: how gut bugs relate to symptoms and progression
A multi-year study will look at gut bacteria and related markers in people with Parkinson’s disease to understand how the gut-brain connection may influence symptoms and progression.
-
Gut-Brain Axis in Parkinson’s Disease: biomarkers and procedures to track progression
A patient-focused program to study how gut health and the brain interact in Parkinson’s disease using biomarkers and clinical procedures.
-
Vitamin D, gut bacteria and dementia risk in older adults with HIV
This work will look at whether low vitamin D and changes in gut bacteria are linked to higher dementia risk in older adults living with chronic HIV and similar community members.
-
Gut bacteria and lung immune cells shape viral lung infections
A study explores how gut microbes affect lung immune cells and severity of respiratory viral infections to identify potential ways to reduce illness.
-
Gut bacteria and Tuft-2 cells linked to early colorectal cancer risk in young Black Americans
This grant aims to understand how gut microbes and Tuft-2 cells may predict aggressive colon adenomas in young Black adults who develop colorectal cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.